Physician profile
Jami Foreback
NPI 1063497543
$645.94
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $74.00 · 2021: $139 · 2022: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $112.04 | 2019-2021 | |
| Abbvie INC. | $72.07 | 2019-2020 | |
| Gilead Sciences, INC. | $60.11 | 2022 | |
| Novo Nordisk INC | $58.58 | 2019-2021 | |
| Pfizer INC. | $45.56 | 2019-2020 | |
| Janssen Biotech, INC. | $42.09 | 2022 | |
| Lilly USA, LLC | $40.42 | 2019-2021 | |
| Cepheid | $32.38 | 2022 | |
| Janssen Pharmaceuticals, INC | $29.97 | 2019-2020 | |
| Abbott Laboratories | $23.92 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.42 | 2021 | |
| Viiv Healthcare Company | $19.52 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.05 | 2021 | |
| Sanofi Pasteur INC. | $15.66 | 2019 | |
| Dexcom, INC. | $15.14 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.49 | 2019 | |
| Shire North American Group INC | $12.50 | 2019 | |
| Amarin Pharma, INC. | $12.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jami Foreback listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.